Bicycle Therapeutics (BCYC) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Bicycle Therapeutics (BCYC) over the past year, gaining 23.1% versus a loss of 53.4%. Over five years, BCYC leads with a -93.7% price change compared with -97.1% for SABS. Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $263.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | SABS |
|---|---|---|
| Share price | $3.81 | $2.89 |
| Market cap | $266.67M | $262.95M |
| 1-day change | +2.14% | +0.35% |
| YTD return | -47.32% | -22.99% |
| 1-year return | -53.37% | +23.08% |
| 5-year return | -93.71% | -97.15% |
| EPS (TTM) | $-2.73 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.16 | $5.15 |
| 52-week low | $3.33 | $2.10 |
| Distance from 52-week high | -58.40% | -43.88% |
| Analyst consensus | none | none |
| Avg. price target upside | +149.34% | +302.77% |
| Average volume | 391.03K | 489.83K |
| Shares outstanding | 50.55M | 90.99M |
| Employees | 288 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed BCYC by 76.5 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
BCYC vs SABS FAQ
Which is bigger, Bicycle Therapeutics or SAB Biotherapeutics?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $262.95M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, BCYC or SABS?
SABS returned +23.08% over the past 12 months, compared with -53.37% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and SAB Biotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Bicycle Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for SAB Biotherapeutics.